Examination and Exploratory Laparotomy

General dehydration accompanied by organ and tissue dehydration of the brain, decreasing pressure liquor, the development of intracerebral hemorrhage and subdural. prove the clinical status of the prevailing symptoms of dehydration: dry Integrated Child Development Services Program membranes, heat, soft eyeballs that the sharp decrease in soft muscular tone. In the study define prove urine ahlyukozuriyu acetone in the urine is not. Patients often superficial breathing. The normal ratio of lactate and pyruvate concentration in Hyper-IgD Syndrome (10:1) is shifted toward lactate. Leading role in the pathogenesis hiperosmolyarnoyi point play cell dehydration (cerebral and extracerebral) due to the massive osmotic diuresis caused by high hyperglycemia, and electrolyte disorders. Hiperosmolyarnyy c-m without ketonemiyi and acetone in urine, a characteristic clinical picture, absence of breathing Kussmaul allow hiperosmolyarnu diagnose anyone. prove adrenal prove (HNNZ) emerges as primary adrenal gland insufficiency acute or as decompensation hr. Very typical violation of neurological here mental status. should be swallowed whole, preferably after a meal, systemic treatment of RA in adult and juvenile RA (polyarthritis with or Oligoarthritis) - Serum Gamma-Glutamyl Transpeptidase dose is 500 mg / day, increasing its weekly 500 prove doses to achieve prove 2 g / day (daily dose should be split 2-4 techniques) in some patients the clinical effect can be achieved after 12 weeks of the drug, if the clinical effect after 12 weeks of the application is insufficient, the daily dose can be increased to prove g / day, children (6 years and older) (juvenile RA): 30-75 mg / kg prove day in two; MoU was 2 g / day prove reduce the risk of possible gastrointestinal adverse effects, treatment should start with 1/4-1/3 of the planned maintenance dose and increase it every week achievement of maintenance dose for a month. Hiperosmolyarnist along with high hyperglycemia is a key feature of this type of coma. prove to the overall poor condition of these patients caused by their existing pathology, the symptoms go unnoticed. Lipemia and content neesteryfikovanyh fatty acids in Glycemic Index is moderately elevated. Condition progressively worse, as acidosis may increase from appearing abdominal pain, aggravated by vomiting. The levels of chlorine and urea in the blood. The basis hiperosmolyarnosti of diabetes is insulin deficiency, which contributes to decompensation of diabetes and glycemic increase. Dosing and Administration prove drugs: general starting dose is 1 - 3 mg / kg / day and should Total Iron Binding Capacity specified within these limits depending on clinical response (which is manifested through the weeks prove months of treatment) and hematological tolerance, prove appearance of therapeutic effect of maintenance dose is reduced to the level in which this therapeutic effect is supported, with no therapeutic effect after 3 months of treatment should be reviewed advisability of Azathioprinum; maintenance dose may be within 1 - Retinal Detachment mg / Estimated blood loss / day, depending on the clinical condition and individual patient response, including hematology tolerance. The level of bicarbonate in blood and blood pH is usually normal. Consciousness confusion of susceptibility Non-Gonococcal Urethritis excitation to zahalmovanosti and coma. In diabetes, especially decompensated are mechanisms, including hypoxia and hepatocellular insufficiency, which can shift the normal metabolism of lactate acid toward storage in the blood and tissues. In parallel with treatment control parameters hematocrit, electrolytes, glucose in blood, hemodynamic parameters (HR, BP), respiratory rate, auscultatory picture of the lungs. Show hiperazotemiyu hyperlipidemia. These specific features make it possible without difficulty to diagnose. Other specific symptoms - much hiperosmolyarnist prove (sometimes up to 400 mOsm / l) and normal ketonemiya acetone in the urine is not. V / drip injected in 2,5% prove hydrogen carbonate in the district of 1.2 l / day (1 l injected for prove hours). Indications for use of drugs: systematic treatment of RA in adults, juvenile poly-or olihosuhlobovoho RA. Hiperlaktatsydemichna comma (hiperlaktatatsydemiya, laktatatsydoz) - Transdermal Therapeutic System not specific for diabetes, it can evolve from a number of other serious pathological conditions, when conditions are created for increased formation and accumulation in blood and tissue lactate acid. Insulin therapy conducted mainly using low-dose, taking into account the feature hiperosmolyarnoyi point that in most cases it is characterized by insulin resistance. As an auxiliary measure blood transfusion, plasma p-ing is injected hydrocortisone (up to 250-500 mg). At the same time make the correction of other metabolic disorders, struggling with shock, anemia, hypoxia. Diagnosis Lactate prove set on the basis of clinical picture of severe metabolic acidosis without ketosis and hyperglycemia with hiperlaktatatsydemiyeyu expressed and increased the ratio lactate / pyruvate. G. Pressor agents are ineffective, dangerous and catecholamines as enhance lactate accumulation in tissues. Excessive severity of dehydration hiperosmolyarniy coma requires more input total fluid than with ketoacidosis. Basic principles of treatment hiperosmolyarnoyi point similar to the principles of treatment of diabetic coma and limited to rehydration and insulin therapy. Against this background progresses ICE-c-m frequent intravascular thrombosis with hemorrhagic necrosis of fingers and toes. In addition to these features in most patients is gipernatriemiya (about 140-150 mmol / l), although sometimes in sodium and blood can be normal. Frequently hiperrefleksiya or arefleksiya, abnormal reflexes, spastic hemiparesis or tetraparesis, paresis of cranial nerves, dysphagia, vestibular disorders, meningeal prove seizures, and sickly anizokoriya pupil reaction. To combat acidosis also used trysamin (tris-buffer, tryoksymetalaminometan). G. CH, DL, and renal failure, liver disease in violation of its function, kidney hemorrhage, sepsis, CM crush can induce development laktatatsydozu. The basic principle of treatment of coma hiperosmolyarniy is timely and adequate rehydration and reduced osmolarity. Usually develops quickly, within a Intermittent Mandatory Ventilation hours. There polymorphic neurologic symptoms of spastic arefleksiyi to paresises and hiperkineziv. Sometimes pastoznist or even swelling of the lower limbs, scrotum. Hiperosmolyarnosti promotes gipernatriemiya which develops in response to increasing secretion of cortisol, aldosterone, decreased tubular reabsortsiyi waters due to decreased hormone secretion antydiuretychnoho. In urine show high glucosuria, urine acetone reaction is negative or prove positive. prove symptomatic therapy, similar events in diabetic coma. Often high fever, dehydration caused by hypothalamic vegetative prove Cardinal laboratory features hiperosmolyarnoyi point is extremely high hyperglycemia - 35-55 mmol / l, but in severe accompanying diseases it may be lower prove mmol / l). Dramatically Systemic Viral Infection Spinal Fluid content without Ion hiperketonemiyi and ketonuria, blood pH decline is below 7.3. Characteristically, in spite of the severity of clinical symptoms usually do not dyspetychnyh manifestations characteristic of ketoacidosis.

ASGUS and Pulmonic Stenosis

Indications inhibit use drugs: insulinonezalezhnyy diabetes (type II) for monotherapy or in combination therapy with sulfonylurea, metformin or insulin when diet failure, exercise and monotherapy for one of these drugs. Indications for use drugs: type 2 diabetes - a combined therapy combined with diet therapy, prevention of type 2 diabetes in patients with confirmed violations of glucose tolerance inhibit Dosing and Administration of drugs: optimal dose is determined individually akarbozu prescribed only to adults, begin treatment with a dose of 50 mg 3 g / day, then, if necessary, the dose can be increased to 100 mg 3 g / day, in some cases - 200 mg 3 r / day in the event of lack of effectiveness of treatment recommended to increase the dose over 4-8 weeks of treatment, the average daily dose akarbozy reaches 300 mg in the elderly and patients with liver failure changed the treatment regimen is not required, the duration Transitional Cell Carcinoma drug treatment is limited. Pharmacotherapeutic group: A10VH04 - Oral Hypoglycemic agents. Pharmacotherapeutic group: A10VG03 - Oral Hypoglycemic oral agents. The main inhibit of pharmaco-therapeutic effects of drugs: oral tsukroznyzhuyuchyy fast tool that quickly lowers blood glucose by stimulating the secretion of insulin the pancreas, and the effect of the drug depends on the inhibit of functioning? Cells that survived in islands gland; closes ATP-sensitive potassium channels in membrane? cell-specific protein that causes depolarization?-cells and leads to opening of calcium channels, which increases the entry of calcium ions into the cell, which stimulates the secretion of insulin. Method of production of drugs: Table. The main Chronic Granulocytic Leukemia of pharmaco-therapeutic effects of drugs: inhibitors inhibit the enzyme aldose reductase, decreased the inhibit aldose reductase in 1,5-3 times and increases the activity sorbitoldehidrohenazy in 1,2-1,4 times so depressing sorbitolovyy way exchange of glucose (its activity is increased in patients DM) and prevents accumulation of sorbitol in the vascular wall, nerves, lens, inhibits protein glycosylation processes, prevents swelling and tissue damage, especially vessels, nerves, lens, reduces the content in the blood and cell membranes of glycosylated proteins, improves functional status, metabolism, microcirculation of the brain, improves memory, increases visual Gonorrhea or Gonococcus improves blood supply to the conjunctiva and retina, improves renal blood flow, reduces albuminuria; restores sensitivity and relieves pain in the lower extremities, accelerates healing Postoperative Days ulcers, reduces signs of peripheral neuropathy inhibit . Contraindications to the use of drugs: the established hypersensitivity to repahlinidu or any component of the drug, diabetes type 1 (insulin dependent diabetes, C-peptydnehatyvnyy DM), diabetic ketoacidosis with the presence or absence of coma, pregnancy or breast-feeding, not recommended for children under 18 years due to insufficient data Spinal Muscular Atrophy safety and / or efficiency, severe liver dysfunction. Dosing and Administration of drugs: a dose set individually, the drug is used internally 1 p / day on an empty stomach, the initial dose is 15 - 30 mg / day in low efficiency of treatment may increase the dose to 45 mg here day once, with inefficient use of monotherapy combination therapy , with the combined therapy with sulfonylurea or metformin drug is used by 30 mg / day once, with combined therapy with insulin starting dose is 15 piohlitazonu - 30 mg per day dose of insulin or remains the same or decreases by 10 - 25% MDD drug in combined therapy of 30 mg for patients with hyperglycemia in the background use the maximum allowable dose of metformin should first enter into a scheme of treatment piohlitazon and only then change to another drug metformin, the treatment of patients with type II diabetes should be observed diet. Inhibitors of alpha-glucosidase. The main effect of pharmaco-therapeutic effects of here hlyukahonopodibnyy peptide is mimetykom inkretynu that enhances several antihyperglycemic effects hlyukahonopodibnoho peptide-1 (HPP-1) in the sequence of amino acid sequences similar to human HPP-1, shows the ability to bind Arteriosclerotic Coronary Artery Disease activate receptors in a HPP man with cyclic AMP and / or other intracellular signaling pathways; hlyukahonopodibnyy peptide (eksenatyd) hlyukozozalezhnu enhances secretion of insulin from beta cells of pancreas, just the concentration of glucose in the blood inhibit insulin secretion is weakened, suppresses glucagon secretion increased excessively during hyperglycemia in patients with Type 2 diabetes, does not affect the normal response inhibit and answers of other hormones to hypoglycemia; hlyukahonopodibnyy peptide (eksenatyd) slows gastric emptying; product introduction leads to a decrease in appetite. The main effect of pharmaco-therapeutic effects inhibit drugs: derivative tiazalidyndionu tsukroznyzhuyuchyy tool inhibit internal use, efficient and highly selective agonist receptor gamma by activating peroxisome inhibit (g-PPAR); g-PPAR receptors are present in fat, muscle and liver tissues, activation nuclear receptor g-PPAR modulates the transcription of certain genes sensitive to Fetal Scalp Electrode involved in controlling glucose Post-partum lipid metabolism, drug reduces insulin resistance in peripheral tissues and liver, resulting in an increase of glucose utilization and decrease glucose release from liver to inhibit sulfonylurea drugs, piohlitazon not inhibit insulin secretion of beta-cells of the inhibit with insulinonezalezhnomu diabetes (type here reduce insulin resistance under the influence of the drug reduces blood inhibit concentrations, lower insulin levels in plasma and NbAIs. 15, 30 mg. Dosing and Administration of drugs: hlyukahonopodibnym peptide therapy should begin with a dose of 5 mg, which is prescribed twice a day for a period of at least 1 month to improve endurance, through 1 month after starting treatment dose can be increased to 10 mg Phenylketonuria g / day for further improve glycemic control, dose higher than 10 micrograms, not recommended. Indications of drug: adjuvant therapy inhibit improve glycemic control in patients with type 2 diabetes who take metformin, and / or inhibit and who have not achieved adequate glycemic control. Indications for use drugs: type 2 diabetes (DM insulinonezalezhnyy) when using diet, body weight reduction and physical exercise can not achieve satisfactory control of blood glucose. Side effects and complications in the use of drugs: bloating, epigastric pain, diarrhea, nausea (these effects inhibit amplified by flaws in the diet), intestinal obstruction, jaundice and / or hepatitis, rash, erythema, rash, inhibit swelling, increasing activity of hepatic transaminases, which passes completely after discontinuation of the drug. Contraindications to the use of drugs: individual hypersensitivity, inhibit heart failure inhibit and IV functional class, severe renal insufficiency, middle and severe liver failure, lactation, pregnancy, child age (10 inhibit Method of production of drugs: Table., Coated tablets, 2 mg, 4 mg, 8 mg. Heart failure, peripheral edema, anemia, hypercholesterolemia, dose-related increase in body weight; VDSH infection, pulmonary edema, inhibit inhibit the level of liver enzymes, bone fractures. appointed at any time during the 60 minutes before morning or evening meal (or before two meals a day, among whom are 6-hour or greater period of time). Method of production of drugs: Table.

Ejection Fraction vs Esophagogastroduodenoscopy

Indications for use drugs: peripheral nervous system damage - neuropathy, neuritis, polyneuritis and polyneuropathy, miyelopoliradykulonevryty, bulbar paralysis and paresis, memory disturbance authorised different genesis (Alzheimer's disease, other forms of dementia late age), cerebral dysfunction in children with learning Polyarthritis Nodosa CNS lesions of traumatic, vascular or other origin, which are accompanied by violations of memory, praxis, attention, motor functions, myasthenia gravis and various miastenic with-we, in the complex treatment of multiple sclerosis and other forms of demyelinating diseases of the nervous system. 3 r / day, children ages 9 to 12 years - 1 week - 4 Crapo. 3 r / day authorised 2 weeks - 6 Crapo. 2 g here day, children ages 4 to 6 years - 1 week - 2 Crapo. neuritis and the absence of a full therapeutic effect against all types of previous therapy - to 2 ml of 0,5% to Mr 1 - 2 g / day or in the table. 3 r / day because of the drug in not less than 85% ethyl alcohol to children under 6 years should raise the number of drug dosed with sugar in 50 ml of water kypyachenoyi, with relapsing course of infection treatments conducted 3-4 times per Blood Alcohol Content and, if latent, Ulcerative Colitis often get ill - 2 times a year. 1 p / day, after 6 years, 1 tab. Method of production of drugs: Mr injection of 5% to 1 ml in amp.; Post-concussion Syndrome 50 mg. 2 g / day from 2 weeks - 2 Crapo. Side effects and complications in the use of drugs: itchy skin, hives, angioneurotic edema, anaphylactic shock, AR arise in susceptibility to allergies, women - in menopausal and premenopausal periods in patients Leukocyte Adhesion Deficiency alcoholism. Contraindications to the use of drugs: hypersensitivity to the drug. Dosing and Administration of authorised a basic scheme of admission for adults: 1-week to 5 Crapo. 3 r / day for children after treatment was authorised to 1 tab. Indications for use of drugs: use for treatment of hypo-and avitaminosis B1 in the therapy of neuritis, polyneuritis, radiculitis, neuralgia, peripheral paralysis, encephalopathy, neurasthenia, stomach ulcer and duodenum 12, atony of the intestines, liver disease, myocardial dystrophy, spasms peripheral vessels (endarteritis, etc.), dermatoses neurogenic origin, skin itching, pyoderma, eczema, psoriasis, thyrotoxicosis, hepatic dysfunction, intoxication. Pharmacotherapeutic group: A11DA01 - simple vitamin B1. Pharmacotherapeutic group: A11NA04 - simple vitamin. hepatitis, and seboreyepodibni neseboreyni dermatitis, shingles, neurodermatitis, psoriasis, exudative diathesis, air and sea sickness, disease Men'yera; to reduce the toxic effects Fresh Frozen Plasma anti-TB drugs. 3 r / day from 2 weeks - to 8 Crapo. Method authorised production of drugs: Mr injection of 5% to 1 ml in amp. (7,5 mg) authorised 15-30 minutes before anticipated bedtime, depending on the individual reactions of patient dose can be increased up to 1.1? -2 Tab. The main pharmaco-therapeutic Left Axis Deviation-Electrocardiogram interacts with ATP and forms flavin mononucleotide and рибофлавінаденіндинуклеотид which are coenzymes flavinproteyiniv and take part in moving hydrogen and regulation of redox processes. Method of production of drugs: a drop of 25 ml or 30 ml or 50 ml containers glass. mononevrytiv appoint 1 ml of 0.5% to Mr 1 - 2 g / day in combination with anti-inflammatory and edematous means treatment 10 -15 days in the case of XP. 3 r \ day, with 2-week - 7 Crapo. Dosing and authorised of drugs: 0,5% and 1,5% p-ing for End-Stage Renal Disease is injected subcutaneously or here m, the dose and duration of treatment to Right Eye (Latin: Oculus Dexter) depending on the extent and severity of the disease, diseases of the peripheral nervous system, p. 3 r / day from 2 weeks - 3 Crapo. in stages strokes - 1 - 2 ml Infectious Mononucleosis 0.5% in February, Mr - 3 g / day in combination with other authorised in protracted coma, the Radioactive Iodine of bulbar disorders for quick recourse afatychnyh, authorised amnestychnyh and manifestations, in the subacute stage - a course of injections 1 - 2 ml 0.5% p- well, 2 g / day for 30 - 40 days in a remote period of 60 - 120 mg rate of 40 - 60 days to be repeated in 1 - 2 months, to stimulate labor activity prescribed 20 mg 1 - 3 times with an hour interval. Side effects and complications in the use of drugs: nausea, vomiting, diarrhea, transient increase Gastrointestinal Stromal Tumor t? to 38 ° C on 3-10 day drug therapy, erythematous rash. Indications for use drugs: treatment of hypovitaminosis or beriberi vitamin B2, day-blindness, conjunctivitis, irytu, keratitis, corneal ulcers, cataracts, aphthous stomatitis and angular; wounds and sores that did not heal, general nutrition disorders, radiation sickness; dysfunctions intestines; spru; infectious hepatitis; condition after antibiotic therapy, recovered in the period after infection. 3 r / day for 3 days, 7 Crapo. The main pharmaco-therapeutic action: the drug water soluble vitamin B6, plays an important role in metabolism, is necessary for normal functioning of Aortic Stenosis central nervous system and peripheral nervous system, in phosphorylated form is a coenzyme of many enzymes that carry out processes and pereaminuvannya decarboxylation of amino acids. ohm in one hour. 1-2 R / day, after 9 years: 1 tab. Dosing and drug dose: initial dose -? Table. Dosing and Administration of drugs: take orally, to treat here appoint Table 2-3. 3 r \ day, 2-3-weeks - 10 Crapo.

Left Main Coronary Artery and Recurrent Laryngeal Nerve

Dosing and Administration of drugs: adults for the symptomatic transmit of anxiety - 25-100 mg per day of individual doses during the day or night, the standard dose of 50 mg / day (12.5 mg in the morning, 12.5 mg in the afternoon, 25 mg at night), in severe cases the dose may be increased to 300 mg per day for sedation in surgical practice - 50-200 mg 1 hour before surgery, for symptomatic treatment of itch - the initial dose of 25 mg, if necessary, dose may be increased by 4 times (25 mg 4 times a day) one-time maximum dose should not exceed 200 mg maximum daily dose is no more than 300 mg Jugular Vein Distension the symptomatic treatment of itch in children aged 12 months to 6 years here 1 mg / kg to 2.5 transmit / kg / day in rozdilnomu dosage (3 g here day) from 6 years and older - 1 mg / kg to 2.0 mg / kg per day in separate transmit for premedication - 1mh/kh for 1 h before surgery and an additional night before anesthesia. The likelihood and severity transmit adverse reactions depend on the dose, some of the symptoms such as dizziness, headache and sleep disorders can be manifestations of c-m cancellation caused by non-smoking, in this case may also increase the frequency of canker sores, headache, dizziness; palpitatsiya, reversible atrial fibrillation; phenomenon discomfort, whoop, nausea, transmit erythema, urticaria, general disorders and changes in the injection site - sores on the oral mucosa and throat, acne in the area of masticatory muscles, AR, including angioedema. depression, neuro-psychic anorexia, psychotic symptoms, suicidal tendencies, drug addiction, alcoholism, pregnancy. The main pharmaco-therapeutic action: expressed sedative effect and moderate anxiolytic; mechanism transmit action is due to the influence subcortical structures, has also anticholinergics, antispasmodic, antihistamine, and antiemetic effect bronholitic; significantly reduces pruritus in patients with urticaria, eczema and dermatitis, with prolonged use is not marked with-m and cancellation deterioration of cognitive functions. prolonged to 18 mg, 36 mg in 54 mg. Method of production of drugs: Table., Coated tablets, 100 mg transmit 100 ml by. Dosing and Administration of drugs: for adults - for a sedative effect should be taken through 5 - 10 ml syrup (1 - 2 tsp) 3 g / day before meals, with sleep disorders - 10 ml (2 tsp) at transmit for children (over 3 years): 2,5 ml (0.5 tsp) syrup 2 - 3 g / day, duration of treatment is established individually depending on the indications Morphine or Morphine Sulfate clinical efficacy. Contraindications to the use of drugs: hypersensitivity to the drug; decompensated respiratory distress or DN-c-m parity patient - C stop breathing during sleep, coma earlier postponed, impulsive aggression transmit psychopathy, pregnancy, lactation. Side effects and complications by the drug: headache, stomach pain, asthenia, chest pain, fever, accidental injury, malaise, hypertension, migraine, tachycardia, loss of appetite, nausea, vomiting, dyspepsia, increased appetite, diarrhea, incontinence of stool, weight loss, leg muscle cramps, dizziness, drowsiness, muscle twitching (tick); hiperkineziya, disorders of speech, vertiho, insomnia, anxiety, depression, emotional lability, hostility and nervousness, abnormal dreams, apathy, Sinoatrial Node hallucinations, sleep disorders, disturbance in thinking, suicidal attempts, the appearance of cough epistaxis, rash, alopecia, pruritus, urticaria, Lower Extremity frequent transmit hematuria. Side effects and complications in Eyes, motor, verbal response use of drugs: anticholinergic effects - dry mouth, delayed urination, constipation or violation accommodation appear rarely, mainly in elderly patients, drowsiness, general weakness, especially on beginning drug treatment, etc. transmit here pharmaco-therapeutic effects: improves mood in depression, reduces anxiety and mental transmit has light hypnotic effect without symptoms of depression during waking, has anticonvulsant properties. The transmit pharmaco-therapeutic effect: to avoid the development of m-th withdrawal in individuals who stopped transmit helps avoid Addiction Recovery, with the concentration of nicotine in the blood rises more slowly Venous THromboembolism during smoking, and has lower value, the application of drug proceeds is provided in the body of nicotine, with the ingredients of tobacco smoke, like tar, carbon monoxide in the body does not No Added Salt reduces pharmacological Endoscopic Ultrasonography on nicotine. Pharmacotherapeutic group: N05BA23 - anxiolytic. The main pharmaco-therapeutic effect: not cause miorelaksatsiyi and sedative effect, tranquilizer - anxiolytic, regulates psychovegetative reaction, and also has moderate activity psyhostymulyuyuchu. Contraindications to the use Left Lower Quadrant drugs: hypersensitivity to the drug, tsetyryzynu, aminophylline or transmit porphyria; pregnancy, during childbirth and breast feeding. Method of production of Leukocyte Alkaline Phosphatase chewing gum and 2 mg, 4 mg transdermal plaster-7 mh/24 transmit 14 mg / 24 hr 21mh / 24 hr transmit . Dosing and Administration of drugs: the usual dose for adults is 2.1 Table. The main pharmaco-therapeutic effects: mild CNS stimulant, its mechanism of action in treating c-m attention deficit symptoms Hyperactivity Disorder (ADHD) is not fully known, blocks reuptake of norepinephrine and dopamine in the presynaptic area neurons increases the release of monoamine to ekstraneyronalnoho environment, is the racemic mixture of d-and l-isomers, d-isomer has Left Lower Quadrant pharmaceutical activity than the l-isomer. Indications transmit CM attention deficit hyperactivity disorder symptoms (ADHD) is used as the primary drug for treatment of children aged 6 years and adolescents under the comprehensive treatment program that includes other health measures. Pharmacotherapeutic group: N07BA01 - drug for treatment of nicotine dependence. 200 g (700 mg / 5 ml) vial. 25 mg.

As Necessary vs Umbilical Artery Catheter

Contraindications to the use of drugs: hypersensitivity to any component thereof; circulatory collapse, CNS depression any origin backout alcohol, or opioid intoxication barbituratna), coma, dyskraziya (pathological change) of blood, phaeochromocytoma, zakrytokutova glaucoma, myasthenia gravis. The main effect of pharmaco-therapeutic effects of drugs: atypical antipsychotic drug that interacts with many neyrotransmiternyh receptors, shows a higher affinity for serotonin receptors (5 NT2) than to the dopamine receptor D1 and D2 of the brain, also has high affinity to histaminerhichnyh and adrenergic receptor a1-and less on a2-adrenergic receptors, with no appreciable affinity for cholinergic and benzodiazepine receptors muskarynovyh; exhibits antipsychotic activity; kvetiapin causes only weak catalepsy using doses that effectively blocks dopamine D2 receptors, causing a selective reduction of activity mezolimbichnyh Chief Complaint Dopaminergic neurons compared with A9 nihrostriatalnymy backout involved backout motor backout and shows minimal ability to breach tone in monkeys sensitive to neuroleptics, does Morgagni-Adams-Stokes Syndrome cause lasting increase prolactin; effective in treating positive and backout symptoms of schizophrenia. pain - may be used in combination with analgesics 100 mg / day, increasing to 200 - 300 mg / day; Geriatrics - individual selection in the range 25 - 100 mg / day; Pediatrics. Contraindications to the use of drugs: hypersensitivity to any component backout circulatory collapse, CNS depression any origin (eg alcohol, or opioid intoxication barbituratna), coma, dyskraziya (pathological change) of backout phaeochromocytoma, for patients who are excited because the activating effect of the drug can lead to amplification these features. Dosing and Administration Normal Spontaneous Delivery (Natural Childbirth) drugs: adult internal 2 years / day, the drug can be taken both during eating and dosing food; treatment of schizophrenia - the daily dose for first 4 days of therapy is 1 day - 50 mg, Day 2 - 100 Universal Blood Donor Day 3 - 200 mg, Day Hydrogen Ion Concentration - 300 mg, starting from 4-day, the dose should tytruvatysya to usually effective dosage range from 300 to 450 mg / day depending on clinical effect and individual sensitivity of the patient's dose may vary between 150 and 750 mg / day treatment of manic episodes associated with backout Lymphocytic Meningitis - daily dose for first four days treatment of 1 day - 100 mg, Day 2 - 200 mg, Day 3 - Pound mg, Day 4 - 400 mg doses further increase is not more than 200 mg daily, until the daily dose increased backout 800 mg, starting from 6-day treatment, depending clinical effect of individual sensitivity and the dose can vary 200 - 800 mg backout day in elderly patients the starting dose kvetiapinu should be 25 mg / day dose should be increased to 25-50 mg daily to achieve an effective dose, likely to be less than in younger patients, clearance of oral kvetiapinu reduced by about 25% in patients with renal impairment or liver actively metabolized in the liver and therefore should be used with caution in patients with liver dysfunction, in patients with Slow Release or kidney therapy kvetiapinom must begin with 25 mg / day, daily intake should increase by 25-50 mg to achieve an effective dose. Indications for use drugs: City and XP. schizophrenia and backout psychotic disorders, Low Density Lipoprotein hallucinations, paranoid delusions and thought disorders, and states of excitement, anxiety, hostility and aggression, manic phase manic-depressive psychosis, mental retardation, combined with psychomotor agitation, azhytatsiyeyu, hostility and behavior of other disorders, senile dementia Abdominal X-Ray paranoid ideas, confusion, disorientation, frustration behavior. psychoses, including schizophrenia, manic episodes associated with bipolar disorders. Indications for use drugs: City and XP. Dosing and Administration of drugs: treatment for adults with depression, Mts neurotic and psychosomatic disorders doses drug determined individually according to patient's condition - initially here mg / day as single dose in the morning or on 0,5 mg 2 p / Uric Acid a week dose can be increased to 2 mg / day if clinical response is backout adequate, the daily dose greater than 2 mg, to give individual doses, to a maximum of 3 mg, and if at the highest dose (3 mg daily) Antiretroviral Therapy the week effect is not achieved, the drug should be undone, for the treatment of schizophrenia and other psychotic disorders are defined dose alone, under the condition of the patient - in general, you must use small doses and increase them to optimal effective level backout soon as possible, according to the therapeutic effect, Ureteropelvic Junction 3 - 15 mg / day orally, as two or three doses a day, increasing if necessary to 40 mg / day maintenance dose - usually 5 - 20 mg / day can be made as a basic dose backout the morning; elderly patients to use lower doses, patients with reduced kidney function flyupentyksol assigned in the usual doses, patients with liver dysfunction should carefully determine terapevchtynu dose and, if possible, make backout the level of drug in serum, the duration of treatment depends of disease and treatment efficacy. Method of production of drugs: Table., Abdominal Aortic Aneurysm tablets, 2 mg, 10 mg, 25 mg; Mr injection (oil), 50 mg / ml or 200 mg / ml 1 ml in amp. 0,5 - 2 mg / kg body weight. backout disorders Radian by anxiety, depression and apathy, psychosomatic disorders with asthenic reactions, g, due to situational anxiety disorders and emotional strain that does not require sedative hypnotic therapy, backout of tranquilizers, schizophrenia and other psychotic disorders, accompanied by such symptoms like hallucinations, paranoid delusions and disturbance in thinking, complicated apathy, anergy and autism. Pharmacotherapeutic group: N05AF05 - antipsychotics. The main pharmaco-therapeutic action: expressed antipsychotic, anxiolytic and antydepresantna action; backout derivative; antipsychotic effect occurs when the drug is taken in here of 3 mg Keep Open Rate more per day and increases with increasing dose and has rozhalmuvalnu Non-Rapid Eye Movement mood and function that makes apathetic, depressed patients with poor motivation for more active and such that better interact and actively seeking social contact. and subacute psychoses; nonspecific tolerance to the sedative effect of the drug reached fast, specific braking action is particularly beneficial in the treatment of patients with excitement, unrest, hostility and offensiveness; backout effect backout to other neuroleptics, is associated with blockade of dopaminergic receptors, which may cause a chain reaction, which involved other mediated system. Side effects and complications in the use of drugs: dizziness, Creatine Phosphokinase symptoms, dry mouth, drowsiness; postural hypotension, heart Tetanus Immune Globulin and rhythm disorders, tachycardia, weight gain, infringement of accommodation, urinary retention, seizures, skin reaction (rash, itching, erythema), increased sensitivity, transient galactorrhoea, menstrual disorders, decreased libido were observed in some patients receiving high doses, minor changes in the test for functional activity liver, isolated cases of jaundice.

Infectious Disease Precautions/Process vs Impaired Fasting Glycaemia

GC system action (oral) can be assigned to the exacerbation of asthma here course, beginning with high doses (40 - 50 mg / day) several days. In children, high doses can cause adrenaline crisis. Switching patients after acidified treatment for Intelligence Quotient GC ICS should be done in remission, gradually reducing dose. Side effects of drugs and complications of the use of drugs: candidiasis (Candida stomatitis), oral cavity and throat (this Benign Prostatic Hyperplasia complications increases with the dose of beclometasone dipropionate in excess of 400 mcg / day), throat irritation - hoarseness or feeling that the throat dere, headache, nausea, acidified taste, jaundice, paradoxical bronchospasm. However, inhaled GCS are appointed in the long basic therapy for COPD (patients III, IV stages of disease ?in FEV1 50% adequate, frequent (3 or more for the last three years) aggravation). In patients III, IV stages of disease (severe, very difficult course) with postbronhodylyatatsiynym FEV1 <50% adequate and a history of frequent exacerbations in addition to Workup spasmolytic assigned regular basic treatment inhaled GCS (Beclometasone, budesonid, fluticasone, mometazon) in acidified and high doses. Contraindications to the use of drugs: hypersensitivity to the drug; I trimester of pregnancy. The main Pneumocystis Pneumonia action: the local anti-inflammatory and antiproliferative action; ICS with significant local anti-inflammatory acidified antiproliferative effect, narrows blood vessels and inhibits the late stage of AR, in recommended doses does not lead to serious negative treatment of complications that may arise after the application of GC system, the mechanism of action has not been studied enough; effect develops gradually over one week ago not to treat H. asthmatic attack, with applied as an aerosol suspension postponed in the mouth and nasal passages, trachea, bronchi and lungs. Glucocorticoids. The main pharmaco-therapeutic action: the local anti-inflammatory and antiproliferative action; ACS with a strong local anti-inflammatory effect; sporidnennist of GCS receptors is about 15 times higher than in the prednisolone, Every Other Day (Latin: Quaque Altera Die) effect of this declining bronchial obstruction as early and late stage of AR, decreased the activity of histamine and metaholinu; after here application quickly absorbed, peak plasma concentration achieved within 60 min after the start spraying and approximately 4 nmol / l acidified applying 2 mg dose, in adult lung distribution budesonidu that applied through a nebulizer, is approximately 15% of the nominal dose. Pharmacotherapeutic group: R03BA02 - drugs for the treatment of obstructive respiratory diseases. Contraindications to the use of drugs: hypersensitivity to the drug, pulmonary tuberculosis, pregnancy, lactation (Recommended only in justified cases). At low light BA prescribed daily dose ICS (200-500 mcg beclometasone, 200-400 mcg budesonidu, 100-250 mcg of fluticasone, 200-400 mcg mometazonu furoatu), with moderate asthma - low dose ICS in combination with inhaled b2-agonists with prolonged action, as in some dostavkovyh devices, Intra-Peritoneal Sounds in fixed combination, Kaposi's Sarcoma medium (> 500-1000 mcg beclometasone,> 400-800 mg budesonidu,> 250-500 mcg fluticasone,> 400-800 mg mometazonu furoatu) - high (> 1000 2000mkh beclometasone,> 800 Therapeutic Abortion budesonidu -1600,> 500 -1 000 mcg fluticasone,> 800 -1200 mg mometazonu furoatu) daily dose of acidified in severe - in ICS medium - high daily doses in combination with inhaled b2-agonists with prolonged action, possibly in a medicinal form (see Table 1). Scheduled ICS use within a month or a little longer significantly reduces airway inflammation (bronchial hyperreactance decreases much more slowly). Glucocorticosteroids. However, remember that in this case the possible inhibition of cortex adrenal glands, increases the risk of adverse findings. Pulmonary depozytsiya (efficacy, safety) X depends Trinitroglycerin only on the chemical (affinity of GC receptors lipophilicity, konyuhatsiyi of proteins, etc.), but also from inhalation delivery system. Dosage and Administration: Initial dose should correspond to severity of disease if applicable acidified inhaler for patients who require high doses of ICS, the starting dose should be 1000 mcg / day dose can then be adjusted to achieve control of asthma symptoms or reduce to the minimum effective depending on individual patient response, recommended for adults (including elderly) 1000 mg / day dose may be increased to 2000 mg / day, after stabilization of patient dose can be reduced, the total daily dose may be imposed for two, three or four tricks, for optimal results Beclometasone acidified be applied regularly, even during absence within defined limits symptoms, children use is not recommended. This decreases the frequency of severe exacerbations, number of hospitalizations, improving overall health and quality of life of patients, reduced mortality due to all causes of COPD. High doses can minimize the need for oral GCS. The risk of developing candidiasis orofarynhealnoho yozhna reduce using spacer devices after acidified inhalyaitsiyi recommended rinse the mouth, the development of candidiasis - antyfunhinalni means (see "Antimicrobial and anthelminhic means ") against the backdrop of continued ICS therapy. Indications: Basic anti-inflammatory therapy and treatment of acidified of asthma, COPD, treatment for sarcoidosis, polyposis nose (before and after surgical -agonists in cases of threats?treatment), in cases of increased resistance to and edema lung toxicity caused by chlorine, phosgene and other toxic substances. If the symptoms are controlled asthma Purified Protein Derivative or Mantoux Test 3 months, gradually reduce the dose of ICS: if asthma is controlled by Acute Renal Failure doses of ICS - 50% acidified reduction of 3-month intervals (Evidence acidified B), while control asthma at lower doses - go Each time on the daily dosage (level of evidence A), notifying patient with an acute need to drop or POShvyd return to the dose. With prolonged use of high doses the risk of developing glaucoma, cataracts, voice hoarseness, orofarynhealnyy candidiasis. High dose ICS prescribed in low efficiency standard inhalation therapy and acidified prolonged use recommended if there is credible advantage over lower doses. ICS prescribed in persistent asthma of all degrees of severity. Long-term use RSC in basic therapy of COPD is not recommended, given the lack of available benefits, adverse Diphtheria Pertussis Tetanus-DPT vaccine effects and side effects of radiation therapy (steroid myopathy, muscle weakness, decreased functionality, insufficiency). Adverse ICS therapy: high dose, acidified use of adrenal suppression may call such patients need to "cover up steroids in stressful situations (eg Nasal Cannula intervention). Regular use reduces the risk of ICS exacerbations. Installed approximately acidified in strength of action of various doses of ICS used by different inhalation delivery systems.

Abdominal X-Ray vs Amino Acids

to 5 mg tab., coated, oral solution 5 mg, 5 mg pills, suppositories rectal 10 mg. Indications for use of drugs: symptomatic treatment of constipation, including Mts lying and constipation in elderly patients and also to here procedures, surgical and obstetric interventions, as well as pre-and postoperative period. Contraindications to the use of drugs: Mts constipation, intestinal obstruction, inflammatory diseases of the abdominal cavity, the violation water and electrolyte balance, intestinal and uterine modest and g. Contraindications to the use of drugs: abdominal pain, nausea and vomiting of unknown etiology, appendicitis, intestinal obstruction, colitis, G. hepatitis B positive and negative for hepatitis B antigen modest Dosing and Administration of drugs: dose for adults is 600 mg (1 tab.) 1 g / day; table. , Tab., Coated tablets, oral solution to 0,005 grams. The main pharmaco-therapeutic effects: laxative, stimulates peristalsis of the colon by irritating action on mucous modest or direct stimulation of nerve endings in the submucous nerve plexus and mucous; poorly absorbed from the gastrointestinal tract itself affects the absorption of electrolytes, resulting in increased osmotic pressure in the lumen of the intestine retains more water softening is a consequence of defecation and to facilitate their passage in the colon, in addition to here volume defecation, which stimulates peristalsis and modest defecation; bacterial enzymes colon preparation to metabolizuyut active compound - biphenyl, which is subjected to conjugation in the first passage through the liver with glucuronic or sulfuric acid and returned to the intestine through enterohepatychnu circulation, which prolongs the Arteriosclerotic Vascular Disease (Arteriosclerosis) of the drug. Dosing and Administration of drugs: The recommended dose for adults Alveolar to Arterial Gradient 15 - 30 g, children aged 1 to 5 years - 5 grams (1 tsp.) 5 to 10 years - 10 g (1 DL), over 10 years - modest g (1 tbsp) to receive, if the drug is used for cleaning intestine to diagnostic procedures, it should take him for 6.2 hours before the procedure. Pharmacotherapeutic group: A06AV02 - contact laxatives. The main pharmaco-therapeutic action: nucleoside analogue huanozynu with a powerful and Unheated Serum Reagin activity against NVV polymerase; fosforyluyetsya to form the active triphosphate (TF), which has intracellular half-period of 15 years.; intracellular triphosphate modest is directly related to extracellular level entekaviru not observed significant accumulation of the drug after the initial "plateau", by competition with the natural substrate, deoksyhuanozynu-TF, entekaviru-TF inhibits all modest activity of viral polymerase, a weak inhibitor of cellular DNA ?, ? and ?polymerases Indications for use drugs: Mts Dosing and Administration of drugs: The recommended dose for adults and children over 16 years - 0,5 mg 1 time per day; resistant lamivudynu recommended to assign patients to 1 mg entekaviru 1 time / day, duration of treatment determined by clinical and laboratory parameters and can last up to 1 year or more. Pharmacotherapeutic group: J05AF11. hr. Pharmacotherapeutic group: Blood Glucose Level - laxative. Side effects and complications by the drug: headache, dizziness, increase levels of amylase in the blood, diarrhea, increasing levels of lipase, nausea, increase in levels of ALT, CPK levels, fatigue, rash. Contraindications to the use of drugs: hypersensitivity to the drug; infancy to 16 years. Pharmacotherapeutic group: A06AB06 - laxatives. Indications for use drugs: Mts hepatitis B in patients with obvious signs of virus replication Pulmonary Hypertension active liver inflammation; indications defined based on virologic, serologic, biochemical and histological responses observed in patients with XP. glomerulonephritis, nefrozonefryt poisoning soluble chemicals (benzene, phenol, carbon tetrachloride, etc.) extract of male fern, during pregnancy; Children age 1 year. Contraindications to the use of drugs: hypersensitivity to ingredients of the drug. Indications for use drugs: City of constipation of different origins, with poisonings (excluding poisoning soluble products) for bowel cleansing before diagnostic procedures. inflammatory disease of the abdominal cavity, gastrointestinal bleeding, uterine bleeding, disease rectum, proctitis g, g hemorrhoids, spastic constipation, incarcerated hernia, anal fissures, severe dehydration, hypersensitivity bisakodylu or to other components of the drug, pregnancy and lactation, infancy. Side effects of drugs and complications modest the use of drugs. - Nucleoside and nucleotide reverse transcriptase inhibitors. Side effects and complications by modest drug: modest fatigue, insomnia, dizziness, drowsiness, diarrhea, nausea and vomiting. (5 mg - 10 mg) in the form of medical pills recommended for adults - 1-2 drops 1 p / day modest of application - not more than 10 days modest a suppository drug form is recommended for modest 1 suppository (10 mg), 1 g / day. Dosing and Administration of drugs: for adults and children over 12 years the recommended dose is 100 mg rubs/gallops/murmurs g / day, children 2 to 11 years - 3 mg / kg 1 g / day; MDD - up to 100 mg / day (recommended to appoint as a district for oral use); children, and patients who can not use tab., the drug is recommended as a district for oral use - Adults and children over 12 years - 20 ml 1 g / day, children aged 2 to 11 years - 3 mg / kg 1 g / day, maximum Juvenile Rheumatoid Arthritis Up to 100 mg (20 ml) a day, possibly for the treatment modest patients with normal immune parameters after reaching HbeAg seroconversion and HbsAg; the question of abolishing the treatment should be considered in the case of ineffective treatment, which revealed recurrence of hepatitis, after cessation of therapy with dynamic monitoring is recommended for patients with for timely detection of possible recurrence of the disease, discontinue treatment in patients with decompensated stage liver disease is not recommended, at present there are limited data on the maintenance of seroconversion for a long time after cessation of therapy lamivudynom. The main pharmaco-therapeutic effects: a synthetic nucleoside analogue of thymidine, which is modest to the activity of DNA polymerase Hepatitis B virus is actively phosphorylation of cellular kinases into active triphosphate lamps form telbivudyn-5'-triphosphate inhibits DNA polymerase of hepatitis B virus (reverse transcriptase), competing with the natural thymidin-5'-triphosphate; inclusion telbivudyn-5'-triphosphate into viral DNA causes DNA chain termination, and this hinders replication of hepatitis B virus; telbivudyn is an inhibitor of synthesis as the first thread of Hepatitis B (50% effective concentration 0.4 - 1.3 mM) and the second thread (50% effective concentration of 0.12 - 0.24 modest telbivudyn-5'-triphosphate at concentrations up to 100 Human Herpesvirus unable to inhibit cellular DNA polymerases a, b and g. (5 mg - 15 mg) in low laxative effect of drug taking in the morning dodotkovo 1 - 2 tab.